Abstract:Background: The AT-rich interaction domain 1A (ARID1A) is thought to be a tumor suppressive gene, and most of its mutations result in loss of expression of ARID1A protein. Combined with SIRPα on the surface of macrophages, CD47 on the surface of cancer cells can send an antiphagocytic "Don't eat me" signal to the immune system that helps to avoid immune surveillance. However, the relationship between ARID1A and CD47 expression and their prognostic value in gastric cancer (GC) are still unknown. Methods: In this study, we evaluated ARID1A and CD47 expression in 154 GC patients' tissues using tissue microarray. Expressions of ARID1A and CD47 in GC cell lines were determined by western blot and quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) techniques, and cell membranous CD47 expression was quantified by flow cytometry. In addition, chromatin immunoprecipitation (ChIP)-qPCR was used to determine the aspects of regulation of CD47 by ARID1A. The proportions of tumor-infiltrating immune cells were estimated on The Cancer Genome Atlas (TCGA) data set by using quanTIseq and EPIC algorithms. The infiltration of M1-polarized macrophages, M2-polarized macrophages, and regulatory T cells (Tregs) in GC tissues was determined by multispectral immunofluorescence. Results: A significant correlation was found between loss of ARID1A and high expression of CD47 at protein level in GC. By integrating 375 bulk RNA sequencing samples from TCGA data set, we found that mutated ARID1A correlated with high CD47 expression. In GC cell lines, knockdown of ARID1A significantly increased CD47 expression both at protein and mRNA levels as measured by western blot, qRT-PCR, and flow cytometry. Moreover, ChIP-qPCR revealed that CD47 was a direct downstream target gene of ARID1A in GC. Utilizing univariate and multivariate survival analyses, we found that patients with ARID1AlossCD47high expression had a worse prognosis. Estimation of infiltrating immune cells on TCGA data set showed that a higher infiltration proportion of M2 macrophages and Tregs was found in ARID1A mutated CD47 high expression subgroup. Furthermore, application of multispectral immunofluorescence revealed a higher infiltration proportion of M2 macrophages and Tregs in ARID1AlossCD47high GC tissues. Conclusion: Loss of ARID1A is strongly correlated with high CD47 expression in GC, and combination of ARID1A and CD47 is a promising prognosis factor in GC.

Loss of BRCA1 Expression Leads to Worse Survival in Patients with Gastric Carcinoma

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

Clinical Outcome and Molecular Landscape of Patients with ARID1A-loss Gastric Cancer.

Measuring Transcripts of Components of the BRCA1 DNA Repair Pathway, Components of the Hippo-Yap Pathway, Β-Trcp, HER2, AEG-1, EZH2 and Other Genes in Advanced Gastric Cancer.

BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.

High Expression of MRE11 Correlates with Poor Prognosis in Gastric Carcinoma

Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency

Expressions of Hmlh1, Hmsh2, C-Myc, and PTEN in Gastric Remnant Cancer and Their Significance

Decreased Expression of BRCA1-associated Protein 1 Predicts Unfavorable Survival in Gastric Adenocarcinoma

A Polymorphism Within The Mismatch Repair Gene Predicts Prognosis And Adjuvant Chemotherapy Benefit In Gastric Cancer Patients.

Loss of ARID1A Expression is Associated with Systemic Inflammation Markers and Has Important Prognostic Significance in Gastric Cancer

Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma.

Decreased Expression of Beclin 1 Correlates with a Metastatic Phenotypic Feature and Adverse Prognosis of Gastric Carcinomas.

Clinical Implication of DNA Damage Response Genes in Advanced Gastric Cancer Stage IV and Recurrent Gastric Cancer Patients After Gastrectomy Treated Palliative Chemotherapy

BRCA1 Mrna Expression As a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy

Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.

Expression of ERCC1,RRM1 and BRCA1 in Tissues of Advanced Non-Small Cell Lung Cancer

Expression and significance of BRCA1 in patients with advanced gastric cancer

Prognostic Value of DNA Repair Gene Based on Stratification of Gastric Cancer.

Combinatorial Analysis of AT-Rich Interaction Domain 1A and CD47 in Gastric Cancer Patients Reveals Markers of Prognosis.

High Expression of PABPC1 Predicts Worse Survival of Gastric Cancer Patients